Although it is commonly accepted that lamivudine prophylaxis should be started a few weeks before chemotherapy is administered, the best time for lamivudine discontinuation is still controversial.
The FDA approves new hepatitis B virus vaccine for adults.
Patients who take aspirin may significantly reduce their risk of hepatitis B-related hepatocellular carcinoma.
Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are diagnosed at an advanced stage of the disease.
Hepatitis B virus reactivation rates differ in patients with inflammatory arthritis.
HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.
The first dose of the hepatitis B vaccine should be given within the first 24 hours of life.
One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access to suitable treatment.
The World Health Organization published a position paper with updated recommendations on the use of the hepatitis B vaccine regarding target groups, immunization schedules, and storage and distribution.
For patients with chronic hepatitis B, achievement of subcirrhotic range of liver stiffness with antiviral therapy is linked to lower risk of hepatocellular carcinoma.
A study showed that telbivudine administered during early and middle pregnancy prevented transmission of hepatitis B virus infection from mother to infants in all participants receiving antiviral treatment.
Hepatocellular carcinoma decreases beyond year 5 of entecavir/tenofovir therapy in Caucasian patients with chronic hepatitis B virus.
The Turkish Society of Rheumatology proposed a guideline of hepatitis screening in patients with rheumatoid arthritis.
Universal vaccination against hepatitis B virus infection prevented non-Hodgkin lymphoma in adolescents in Taiwan, an endemic area for hepatitis B virus infection.
Hepatitis B virus reactivation has become a safety concern in patients with HBV and HCV coinfection receiving direct-acting antiviral agents.
Women with a high hepatitis B viral load who receive tenofovir during pregnancy have a significantly reduced risk for passing on the virus to their child, without an increase in the risk of adverse events.
The new European Association for the Study of the Liver (EASL) clinical practice guidelines for hepatitis B virus infection identifies new management strategies for an incurable disease.
Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and, to a lesser extent, in patients with alcohol-induced cirrhosis. Mortality rates were also reduced in statin users with HBV-related cirrhosis.
While prior studies have found an association between hepatitis C and the risk for Parkinson disease, the association between hepatitis B and Parkinson disease is new and needs further confirmation.
Despite being the seventh leading cause of death in the world, viral hepatitis accounts for less than 1% of the National Institutes of Health research budget.
Hepatitis B virus reactivation may occur in patients with chronic hepatitis C with current HBV infection treated with direct-acting antivirals.
Long-term treatment with tenofovir for hepatitis B virus infection is associated with hypophosphatemia and elevated serum levels of fibroblast growth factor 23, a hormone that induces renal phosphate excretion.
The American College of Gastroenterology released a set of guideline for evaluating abnormal liver chemistries.
Meta-analysis provides further support to findings that show a protective role of antibody to hepatitis B surface antigen against reactivation in patients with resolved HBV undergoing chemotherapy for hematologic tumors without antiviral prophylaxis.
Three-dose tocilizumab combined with csDMARDs might increase the risk of HBV reactivation in RA patients with chronic HBV infection.
Patients with breast cancer who have chronic HBV infection have fewer flares while undergoing chemotherapy if they are treated with prophylactic lamivudine.
Evotaz label has been updated to include data from Trial 114 including updates to the drug interactions and specific populations sections.
The new HBV test service from Quest Diagnostics measures the quantity of viral antigen to determine if the immune system is responding to treatment.
Meta-analysis shows consistent evidence that in advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival is dependent on patients' hepatitis status.
Combination antiretroviral therapy is associated with an overall reduction in liver fibrosis in HIV-infected patients with and without hepatitis co-infections.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Pediatric Outpatient Antimicrobial Stewardship: Minimizing Antibiotic Duration
- Are Antibiotic Stewardship Programs the Antidote to Antibiotic Overuse?
- Better Detection and Treatment Needed for H pylori Infections in Children
- FDA Approves New Hepatitis B Vaccine for Adults
- Strategies for Preventing Antibiotic Resistance in Acne